healthcare

Trade worries remained a headwind for the market as investors and traders continued to mull the threat of increased U.S. tariffs on Chinese goods even as they awaited the outcome of trade talks this week between the world’s two largest economies. The market appears to not have been able to...

After returning from a long weekend, investors and traders appear to be gearing up for a busy week on the earnings front as they continue awaiting a potential trade deal between the United States and China. In general, earnings season is turning out to be better than analysts expected, although...

On the last trading day of the week, investors were greeted with some mixed economic data as earnings season is turning out to be better than expected. U.S. retail sales for March came in stronger than forecast, notching a 1.6% gain when a Briefing.com consensus showed expectations of a 0.9% rise....

Owens & Minor (NYSE: OMI), a healthcare logistics company, is exploring a sale of itself after a series of disappointing earnings reports, according to sources quoted by Reuters in an exclusive report. The $420 million company, by market capitalization, lost 20 percent of its stock value this...

CVS Health Corporation (NYSE: CVS) is one step closer to acquiring Aetna Inc. (NYSE: AET) after the U.S. Department of Justice preliminary approved the $69 billion merger. What Happened CVS proposed to buy Aetna in late 2017 in a deal that would combine the largest drugstore chain with Aetna's...

The bearish case for Eli Lilly And Co (NYSE: LLY)'s stock is based on multiple concerns, but the stock's decline since the beginning of the year implies a better risk-to-reward profile, according to BMO Capital Markets.  The Analyst BMO's Alex Arfaei upgraded Eli Lilly from...

President Donald Trump's tax reform victory could positively impact the health care sector and fuel a new round of M&A activity, according to one analyst.  The Analyst Height Healthcare's Shrey Verma and Andrea Harris. The Thesis Corporate tax reform is expected to fuel health...

Hospital stocks are in line to profit off potential tax reform, but that might be where the good news ends. Morgan Stanley expects a potentially radical shift in health care services toward payer vertical integration to shake the industry and strain traditional competitors. The Rating Analyst...

The health care sector could see another notable merger, as insurer Humana Inc (NYSE: HUM) is reportedly in talks to acquire the acute care provider Kindred Healthcare, Inc. (NYSE: KND). The Analyst Bank of America Merrill Lynch's Kevin Fischbeck is no longer rating Kindred Healthcare...

Recent developments in the healthcare space, including the proposed merger between CVS Health Corp (NYSE: CVS) and Aetna Inc (NYSE: AET), bodes well for Express Scripts Holding Company (NASDAQ: ESRX). The Analyst Bernstein's Lance Wilkes upgraded Express Scripts from Underperform to...

CVS Health Corp (NYSE: CVS) and Aetna Inc (NYSE: AET) agreed to merge over the weekend, and some of Wall Street's top analysts released their initial take on the deal. The Analyst Baird's Eric Coldwell maintains a Neutral rating on CVS' stock with an unchanged $77 price target...

CVS Health Corp (NYSE: CVS) and Aetna Inc (NYSE: AET) confirmed in a joint announcement on Sunday that the two companies reached an agreement to merge after weeks of speculation. What You Need To Know CVS will acquire Aetna in a deal worth approximately $69 billion ($77 billion including Aetna...

CVS Health Corp (NYSE: CVS)'s proposed acquisition of health insurer Aetna Inc (NYSE: AET) could be seen as a move to better defend itself should Amazon.com, Inc. (NASDAQ: AMZN) flex its muscles and enter the drug space. The Analyst Needham's Kevin Caliendo. The Rating Caliendo upgraded...

Shares of Acadia Healthcare Company Inc (NASDAQ: ACHC) plummeted 25 percent after the behavioral healthcare services company with operations in the U.S. and U.K. reported disappointing third-quarter earnings. In reaction to the earnings report, Baird's Whit Mayo downgraded Acadia's stock...

Analysts at Goldman Sachs turned bearish on industry giant Johnson & Johnson (NYSE: JNJ) amid valuation concerns. Analyst Jami Rubin downgraded J&J's stock from Neutral to Sell with a price target boosted from $125 to $130, which implies downside from Wednesday's open of $133.25....